Emma Sampson

Oct 26, 2023 | psiquiatria.com | Emma Sampson |Natalie T. Mills

Objetivo El trastorno depresivo mayor (TDM) sigue siendo difícil de tratar, y muchos pacientes se resisten a los tratamientos existentes o experimentan recaídas. La disfunción cognitiva se asocia con resultados clínicos más graves. La vortioxetina ha demostrado eficacia para remediar el deterioro cognitivo asociado a la depresión.

Oct 4, 2023 | psychiatrist.com | Emma Sampson |Natalie T. Mills |Hikaru Hori |Kathrin Schwarte

ABSTRACTObjective: Major depressive disorder (MDD) remains difficult to treat, with many patients resistant to existing treatments or experiencing relapse. Cognitive dysfunction is associated with more severe clinical outcomes. Vortioxetine has shown efficacy in remediating depression-associated cognitive impairment. Anti-inflammatory augmentation of antidepressants is a new strategy in treating depression and has not previously been assessed for effects on cognition in depression.

Aug 27, 2023 | onlinelibrary.wiley.com | Erhan Kavakbasi |Emma Sampson |Natalie T. Mills |Hikaru Hori

CI confidence interval COX-2 cyclooxygenase-2 CRP C-Reactive Protein IL interleukin IQR interquartile range hsCRP high-sensitivity C-Reactive Protein MADRS Montgomery–Åsberg Depression Rating Scale MDD major depressive disorder MCP-1 monocyte chemoattractant protein MMRM linear mixed-effects models for repeated measures PGE2 prostaglandin E2 RCT randomized controlled trial TNF-α tumor necrosis factor alpha 1 INTRODUCTION Major depressive disorder (MDD) is a common mental health problem...